Inclusion Criteria:  patients divided in :  Patients with low risk prostate cancer (Gleason score ≤ 6 and cT1-T2a and Prostate Specific Antigen (PSA) value < 10 ng/mL); Patients with intermediate risk prostate cancer (Gleason score 7 or cT2b or PSA value 10-20 ng/mL); Patients with high risk prostate cancer (Gleason > 7 or cT2c or PSA value > 20 ng/mL); Candidate for radical prostatectomy after discussion in multidisciplinary committee; Written informed consent willingly obtained.  Exclusion Criteria:  Any kind of previous treatment for prostate cancer (hormonal treatment, EBRT, brachytherapy, cryotherapy, etc…); Patient not candidate for radical prostatectomy and/or unable to benefit from surgery; Patient under legal protection or unable to express its own consent; Patient within exclusion period from another clinical trial; Claustrophobia (unable to accept PET/CT scanning).